[Treatment of herpes zoster with cytarabine (author's transl)].
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001327:Autoimmune Diseases / Q000150:complications; D055598:Chemical Phenomena; D002621:Chemistry; D003561:Cytarabine / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006560:Herpes Labialis / Q000150:complications / Q000188:drug therapy; D006562:Herpes Zoster / Q000150:complications / Q000188:drug therapy*; D006563:Herpes Zoster Ophthalmicus / Q000188:drug therapy; D006689:Hodgkin Disease / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007275:Injections, Intravenous; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications; D008297:Male; D008875:Middle Aged
D007166:Immunosuppressive Agents; D003561:Cytarabine
Die Behandlung des Zoster mit Cytarabin.